The successful clinical translation of SL-401 and CD123CAR T cells has fueled active development in other CD123-targeted immunotherapies, including BsAb, for treating BPDCN and various CD123-related hematologic malignancies. The gene discussed is IL3RA; the disease is hematologic disorder.